Celltrion to build a $94M+ facility in South Korea — report

Ko­re­an biosim­i­lar mak­er Cell­tri­on will be con­struct­ing a new man­u­fac­tur­ing fa­cil­i­ty in South Ko­rea.

A re­port from Ko­rea Bio­med­ical Re­view on Tues­day said that Cell­tri­on will spend KRW 126 bil­lion, or $94.4 mil­lion, on a new drug prod­uct man­u­fac­tur­ing fa­cil­i­ty lo­cat­ed at its cam­pus in Song­do, South Ko­rea, just south­west of Seoul.

The re­port said the new fac­to­ry is slat­ed to be fin­ished some­time in the be­gin­ning of 2026 and will start pro­duc­tion in 2027. The fa­cil­i­ty will al­so pro­duce “8 mil­lion liq­uid vials an­nu­al­ly.” The re­port did not give de­tails on the size or head­count at the fa­cil­i­ty. End­points News con­tact­ed Cell­tri­on for more in­for­ma­tion but did not get an im­me­di­ate re­sponse.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.